DeutschNewstral
Article
Ddcourier.com on 2023-12-12 00:36
Eli Lilly slumps after disappointing Zepbound weight-loss-drug trial
Related news
- TEli Lilly slumps after slashing profit outlook despite weight-loss drug earnings boostthestreet.com
Eli Lilly weight loss drug Zepbound approved by the FDANew York Post- TEli Lilly leaps as weight-loss-drug sales drive earnings and 2024 outlookthestreet.com
Eli Lilly & Co: Eli Lilly weight-loss drug found to address sleep apnoea in trialFinancial Times- MEli Lilly weight reduction drug tirzepatide knowledge launchedmvtelegraph.com
Weight Loss Drug Zepbound May Reduce Sleep Apnea, Eli Lilly SaysForbes- DEli Lilly slashes 2023 profit outlook despite weight-loss drug earnings boostdcourier.com
- Eli Lilly Pushes For Fast-Track Approval Of Mounjaro As Weight-Loss DrugForbes
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroStar Tribune- MEli Lilly faucets Amazon Pharmacy to assist ship Zepbound, different medicationmvtelegraph.com
- Eli Lilly launches website, home delivery option for Wegovy alternative ZepboundNew York Post
Sleep Apnea Reduced in People Who Took Zepbound, Eli Lilly ReportsThe New York Times- Eli Lilly & Co: Eli Lilly to seek US approval after Alzheimer’s drug trial successFinancial Times
- Eli Lilly & Co: Eli Lilly to seek obesity drug approval that could disrupt weight loss marketFinancial Times
- Eli Lilly & Co: Eli Lilly to invest extra $5.3bn in manufacturing site for weight loss drugsFinancial Times
- FEli Lilly & Co: Eli Lilly races to boost capacity for rival to Novo Nordisk weight-loss drugft.com
US stocks edge higher after a big week; Eli Lilly slumpsTimesDaily.com